Effects of adolescent nicotine and SR 147778 (Surinabant) administration on food intake, somatic growth and metabolic parameters in rats

Neuropharmacology

Volumn 54, Issue 1, 2008, Pages 194-205

  Lamota, Laura ^a   Bermudez Silva, Francisco Javier ^b   Marco, Eva María ^a   Llorente, Ricardo ^a   Gallego, Araceli ^a   Rodríguez de Fonseca, Fernando ^b   Viveros, María Paz ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Adolescence; Body weight; Cannabinoid; Food intake; Metabolism; Nicotine; Surinabant

Indexed keywords

5 (4 BROMOPHENYL) 1 (2,4 DICHLOROPHENYL) 4 ETHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; ADIPONECTIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; NICOTINE TARTRATE; SURINABANT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY GROWTH; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; LIPID METABOLISM; MALE; METABOLIC PARAMETERS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SEX DIFFERENCE; SMOKING CESSATION; TOBACCO DEPENDENCE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

AGE FACTORS; ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; BEHAVIOR, ANIMAL; BLOOD GLUCOSE; BODY WEIGHT; CHOLESTEROL, HDL; DISEASE MODELS, ANIMAL; EATING; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HORMONES; LIPID METABOLISM; MALE; NICOTINE; PIPERIDINES; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; SEX FACTORS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 37349076542     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2007.07.004     Document Type: Article

References (61)

1. Abreu-Villaca Y., Seidler F.J., Qiao D., Tate C.A., Cousins M.M., Thillai I., and Slotkin T.A. Short-term adolescent nicotine exposure has immediate and persistent effects on cholinergic systems: critical periods, patterns of exposure, dose thresholds. Neuropsychopharmacology 28 (2003) 1935-1949
2. Andersson K., and Arner P. Systemic nicotine stimulates human adipose tissue lipolysis through local cholinergic and catecholaminergic receptors. Int. J. Obes. Relat. Metab. Disord. 25 (2001) 1225-1232
3. Bellinger L., Cepeda-Benito A., and Wellman P.J. Meal patterns in male rats during and after intermittent nicotine administration. Pharmacol. Biochem. Behav. 74 (2003) 495-504
4. Bellocchio L., Mancini G., Vicennati V., Pasquali R., and Pagotto U. Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases. Curr. Opin. Pharmacol. 6 (2006) 586-591
5. Bermudez-Siva F.J., Serrano A., Diaz-Molina F.J., Sanchez-Vera I., Juan-Pico P., Nadal A., Fuentes E., and Rodriguez de Fonseca F. Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur. J. Pharmacol. 531 (2006) 282-284
6. Biscaia M., Marin S., Fernandez B., Marco E.M., Rubio M., Guaza C., Ambrosio E., and Viveros M.P. Chronic treatment with CP 55,940 during the peri-adolescent period differentially affects the behavioural responses of male and female rats in adulthood. Psychopharmacology (Berl.) 170 (2003) 301-308
7. Bishop C., Parker G.C., and Coscina D.V. Nicotine and its withdrawal modify dorsal raphe 8-hydroxy-2-(di-n-propylamino) tetralin feeding. Pharmacol. Biochem. Behav. 74 (2003) 961-967
8. Cervino C., Pasquali R., and Pagotto U. Cannabinoid receptor antagonists and the metabolic syndrome: novel promising therapeutical approaches. Mini Rev. Med. Chem. 7 (2007) 21-30
9. Cohen C., Kodas E., and Griebel G. CB1 receptor antagonists for the treatment of nicotine addiction. Pharmacol. Biochem. Behav. 81 (2005) 387-395
10. Cohen C., Perrault G., Griebel G., and Soubrie P. Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, Rimonabant (SR141716). Neuropsychopharmacology 30 (2005) 145-155
11. Cota D., Marsicano G., Tschop M., Grubler Y., Flachskamm C., Schubert M., Auer D., Yassouridis A., Thone-Reineke C., Ortmann S., Tomassoni F., Cervino C., Nisoli E., Linthorst A.C., Pasquali R., Lutz B., Stalla G.K., and Pagotto U. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Investig. 112 (2003) 423-431
12. Crisp A.P., Sedgwick C., Halek N., and Joughin Humphrey H. Why may teenage girls persist in smoking?. J. Adolesc. 22 (1999) 657-672
13. Croft J.B., Freedman D.S., Cresanta J.L., Srinivasan S.R., Burke G.L., Hunter S.M., Webber L.S., Smoak C.G., and Berenson G.S. Adverse influences of alcohol, tobacco, and oral contraceptive use on cardiovascular risk factors during transition to adulthood. Am. J. Epidemiol. 126 (1987) 202-213
14. Cryan J.F., Gasparini F., van Heeke G., and Markou A. Non-nicotinic neuropharmacological strategies for nicotine dependence: beyond bupropion. Drug Discov. Today 8 (2003) 1025-1034
15. Després J.P., Golay A., Sjöström L., and Rimonabant in Obesity-Lipids Study Group. Effects of Rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 353 (2005) 2121-2134
16. Di Marzo V., and Matias I. Endocannabinoid control of food intake and energy balance. Nat. Neurosci. 8 (2005) 585-589
17. Doggrell S.A. Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over Rimonabant?. Expert Opin. Investig. Drugs 14 (2005) 339-342
18. Doyon C., Denis R.G., Baraboi E.D., Samson P., Lalonde J., Deshaies Y., and Richard D. Effects of Rimonabant (SR141716) on fasting-induced hypothalamic-pituitary-adrenal axis and neuronal activation in lean and obese Zucker rats. Diabetes 55 (2006) 3403-3410
19. Faraday M.M., Blakeman K.H., and Grunberg N.E. Strain and sex alter effects of stress and nicotine on feeding, body weight, and HPA axis hormones. Pharmacol. Biochem. Behav. 80 (2005) 577-589
20. File S.E., Fluck E., and Leahy A. Nicotine has calming effects on stress-induced mood changes in females, but enhances aggressive mood in males. Int. J. Neuropsychopharmacol. 4 (2001) 371-376
21. Filozof C., Fernandez Pinilla M.C., and Fernandez-Cruz A. Smoking cessation and weight gain. Obes. Rev. 5 (2004) 95-103
22. Gessa G.L., Serra S., Vacca G., Carai M.A., and Colombo G. Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats. Alcohol Alcohol. 40 (2005) 46-53
23. Gomez R., Navarro M., Ferrer B., Trigo J.M., Bilbao A., Del Arco I., Cippitelli A., Nava F., Piomelli D., and Rodriguez de Fonseca F. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J. Neurosci. 22 (2002) 9612-9617
24. Guillon M.S., Crocq M.A., and Bailey P.E. Nicotine dependence and self-esteem in adolescents with mental disorders. Addict. Behav. 32 (2007) 758-764
25. Iwashima Y., Katsuya T., Ishikawa K., Kida I., Ohishi M., Horio T., Ouchi N., Ohashi K., Kihara S., Funahashi T., Rakugi H., and Ogihara T. Association of hypoadiponectinemia with smoking habit in men. Hypertension 45 (2005) 1094-1100
26. Jbilo O., Ravinet-Trillou C., Arnone M., Buisson I., Bribes E., Peleraux A., Penarier G., Soubrie P., Le Fur G., Galiegue S., and Casellas P. The CB1 receptor antagonist Rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J. 19 (2005) 1567-1569
27. Jo Y.H., Talmage D.A., and Role L.W. Nicotinic receptor-mediated effects on appetite and food intake. J. Neurobiol. 53 (2002) 618-632
28. Juan-Pico P., Fuentes E., Bermudez-Silva F.J., Diaz-Molina F.J., Ripoll C., Rodriguez de Fonseca F., and Nadal A. Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium 39 (2006) 155-162
29. Kirkham T.C. Endocannabinoids in the regulation of appetite and body weight. Behav. Pharmacol. 16 (2005) 297-313
30. Lallemand F., and De Witte P. SR147778, a CB1 cannabinoid receptor antagonist, suppresses ethanol preference in chronically alcoholized Wistar rats. Alcohol 39 (2006) 125-134
31. Li M.D., Kane J.K., and Konu O. Nicotine, body weight and potential implications in the treatment of obesity. Curr. Top. Med. Chem. 3 (2003) 899-919
32. Liu R.H., Mizuta M., and Matsukura S. The expression and functional role of nicotinic acetylcholine receptors in rat adipocytes. J. Pharmacol. Exp. Ther. 310 (2004) 52-58
33. Lopez-Moreno J.A., Trigo-Diaz J.M., Rodriguez de Fonseca F., Gonzalez Cuevas G., Gomez de Heras R., Crespo Galan I., and Navarro M. Nicotine in alcohol deprivation increases alcohol operant self-administration during reinstatement. Neuropharmacology 47 (2004) 1036-1044
34. Marco E.M., Granstrem O., Moreno E., Llorente R., Adriani W., Laviola G., and Viveros M.P. Subchronic nicotine exposure in adolescence induces long-term effects on hippocampal and striatal cannabinoid-CB1 and mu-opioid receptors in rats. Eur. J. Pharmacol. 557 (2007) 37-43
35. Marco E.M., Llorente R., Moreno E., Biscaia J.M., Guaza C., and Viveros M.P. Adolescent exposure to nicotine modifies acute functional responses to cannabinoid agonists in rats. Behav. Brain Res. 172 (2006) 46-53
36. Matias I., and Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol. Metab. 18 (2007) 27-37
37. Moreno M., Escuredo L., Munoz R., Rodríguez de Fonseca F., and Navarro M. Long-term behavioural and neuroendocrine effects of perinatal activation or blockade of CB1 cannabinoid receptors. Behav. Pharmacol. 16 (2005) 423-430
38. Mittendorfer B. Sexual dimorphism in human lipid metabolism. J. Nutr. 135 (2005) 681-686
39. Murrin L.C., and Ferrer J.R. Nicotine administration to rats: methodological considerations. Life Sci. 40 (1987) 1699-1708
40. Navarro M., Rubio P., and Rodríguez de Fonseca F. Behavioural consequences of maternal exposure to natural cannabinoids in rats. Psychopharmacology (Berl.) 122 (1995) 1-14
41. Osei-Hyiaman D., DePetrillo M., Pacher P., Liu J., Radaeva S., Batkai S., Harvey-White J., Mackie K., Offertaler L., Wang L., and Kunos G. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Investig. 115 (2005) 1298-1305
42. Pagotto U., Marsicano G., Cota D., Lutz B., and Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr. Rev. 27 (2006) 73-100
43. Perkins K.A., Donny E., and Caggiula A.R. Sex differences in nicotine effects and self-administration: review of human and animal evidence. Nicotine Tob. Res. 1 (1999) 301-315
44. Perwitz N., Fasshauer M., and Klein J. Cannabinoid receptor signaling directly inhibits thermogenesis and alters expression of adiponectin and visfatin. Horm. Metab. Res. 38 (2006) 356-358
45. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., Devin J., Rosenstock J., and RIO North America Group. Effect of Rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. J. Am. Med. Assoc. 295 (2006) 761-775
46. Pomerleau C.S., Ehrlich E., Tate J.C., Marks J.L., Flessland K.A., and Pomerleau O.F. The female weight-control smoker: a profile. J. Subst. Abuse 5 (1993) 391-400
47. Reseland J.E., Mundal H.H., Hollung K., Haugen F., Zahid N., Anderssen S.A., and Drevon C.A. Cigarette smoking may reduce plasma leptin concentration via catecholamines. Prostaglandins Leukot. Essent. Fatty Acids 73 (2005) 43-49
48. Rinaldi-Carmona M., Barth F., Congy C., Martinez S., Oustric D., Perio A., Poncelet M., Maruani J., Arnone M., Finance O., Soubrie P., and Le Fur G. SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization. J. Pharmacol. Exp. Ther. 310 (2004) 905-914
49. Rodriguez de Fonseca F., Cebeira M., Ramos J.A., Martin M., and Fernandez-Ruiz J.J. Cannabinoid receptors in rat brain areas: sexual differences, fluctuations during estrous cycle and changes after gonadectomy and sex steroid replacement. Life Sci. 54 (1994) 159-170
50. Rodriguez de Fonseca F., Fernandez-Ruiz J.J., Murphy L., Eldridge J.C., Steger R.W., and Bartke A. Effects of delta-9-tetrahydrocannabinol exposure on adrenal medullary function: evidence of an acute effect and development of tolerance in chronic treatments. Pharmacol. Biochem. Behav. 40 (1991) 593-598
51. Sanguino E., Bejarano R., Alegret M., Sanchez R.M., Vazquez-Carrera M., and Laguna J.C. Sexual dimorphism in lipid metabolic phenotype associated with old age in Sprague-Dawley rats. Exp. Gerontol. 39 (2004) 1295-1306
52. Schwimmer J.B., Deutsch R., Kahen T., Lavine J.E., Stanley C., and Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 118 (2006) 1388-1393
53. STRATUS-US. 2006. Available from http://www.acompliareport.com/Studies/STRATUS-US.htm.
54. Tucci S.A., Halford J.C., Harrold J.A., and Kirkham T.C. Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation. Curr. Med. Chem. 13 (2006) 2669-2680
55. Van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., Rossner S., and RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker Rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
56. Vickers P., and Kennett G.A. Cannabinoids and the regulation of ingestive behaviour. Curr. Drug Targets 6 (2005) 215-223
57. Viveros M.P., Llorente R., Moreno E., and Marco E.M. Behavioural and neuroendocrine effects of cannabinoids in critical developmental periods. Behav. Pharmacol. 16 (2005) 353-362
58. Viveros M.P., Marco E.M., and File S.E. Nicotine and cannabinoids: parallels, contrasts and interactions. Neurosci. Biobehav. Rev. 30 (2006) 1161-1181
59. Yoon M., Jeong S., Nicol C.J., Lee H., Han M., Kim J.J., Seo Y.J., Ryu C., and Oh G.T. Fenofibrate regulates obesity and lipid metabolism with sexual dimorphism. Exp. Mol. Med. 34 (2002) 481-488
60. Yoshida T., Sakane N., Umekawa T., Kogure A., Kondo M., Kumamoto K., Kawada T., Nagase I., and Saito M. Nicotine induces uncoupling protein 1 in white adipose tissue of obese mice. Int. J. Obes. Relat. Metab. Disord. 23 (1999) 570-575
61. Yoshikawa H., Hellstrom-Lindahl E., and Grill V. Evidence for functional nicotinic receptors on pancreatic beta cells. Metabolism 54 (2005) 247-254